StockNews.com initiated coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research note published on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.
22nd Century Group Stock Performance
Shares of NASDAQ:XXII opened at $0.12 on Friday. The firm has a market cap of $962,701.20, a PE ratio of 0.00 and a beta of 1.39. The firm’s 50 day simple moving average is $0.29 and its 200-day simple moving average is $0.81. 22nd Century Group has a one year low of $0.09 and a one year high of $8.81.
22nd Century Group (NASDAQ:XXII – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.36) EPS for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%. The firm had revenue of $7.95 million for the quarter.
Institutional Inflows and Outflows
22nd Century Group Company Profile
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Articles
- Five stocks we like better than 22nd Century Group
- What is the S&P 500 and How It is Distinct from Other Indexes
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Invest in Small Cap StocksĀ
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Canada Bond Market Holiday: How to Invest and Trade
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.